Who founded Algen Biotechnologies?

Algen Biotechnologies was founded by Chun-Hao Huang, Christine Du, Jennifer Doudna in 2018.

Who are Algen Biotechnologies's investors?

Algen Biotechnologies's investors include Cota Capital, Draper Associates, Lifespan Vision Ventures, Rebel Fund, Y Combinator, Sequoia Capital, Viking Global.

Where is Algen Biotechnologies headquartered?

Algen Biotechnologies is headquartered in San Francisco, US.

Algen Biotechnologies

YC W20

San Francisco, US · Founded 2018 · 15 employees · 7 known investors

Find your way into Algen Biotechnologies

Paths you didn't know you had: your email and LinkedIn already hold routes to the Algen Biotechnologies team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Algen Biotechnologies discovers and develops small molecule therapeutics for cancer and inflammatory diseases using CRISPR, RNAi, and machine learning to decode functional gene networks and predict drug responses.

Also known as Inc.

AI & Machine Learning Biotech Deep Tech Healthtech Medical Devices CRISPR Therapeutics Drug discovery AIUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (W20)

Algen Biotechnologies was founded in 2018 by Chun-Hao Huang, Christine Du, and Jennifer Doudna.

Chun-Hao Huang Co-Founder & CEOChun-Hao Huang is co-founder and CEO of Algen Biotechnologies, which develops small molecule therapeutics for cancer and inflammatory diseases using CRISPR, RNAi, and machine learning to identify functional gene networks and predict drug responses.

Christine Du Co-Founder & CBOChristine Du is co-founder and chief business officer of Algen Biotechnologies, which develops small molecule therapeutics for cancer and inflammatory diseases using CRISPR, RNAi, and machine learning.

Jennifer Doudna

Dr. Jeff WhittenChief Scientific Officer

Investors · 7

Cota Capitallisted by Cota CapitalSan Francisco

How we know: Cota Capital's portfolio page · Y Combinator's founder network · Not right? Tell us

Draper Associateslisted by Draper AssociatesSan Mateo · $500K – $5M

How we know: Draper Associates's portfolio page · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

Lifespan Vision Ventureslisted by Lifespan Vision VenturesNorwalk

Rebel Fundlisted by Rebel FundSan Francisco · $100K – $5M

How we know: Rebel Fund's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Y Combinator's founder network · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us

Sequoia CapitalreportedMenlo Park · $100K – $50M

How we know: Y Combinator's founder network · Not right? Tell us

Viking GlobalreportedStamford

How we know: Y Combinator's founder network · Not right? Tell us

Related companies · 6

LEAH LabsLEAH Labs engineers gene-edited CAR-T cell therapies to treat cancer in pet dogs, with the goal of generating translational insights for human cancer therapy. The company uses proprietary gene editing and protein design to develop therapeutic treatments for companion animal oncology.

Generate BiomedicinesGenerate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering. The company creates new drugs on demand across diverse biologic modalities for immunology, oncology, infectious disease, and vaccines.

NephrogenNephrogen develops AI-powered AAV delivery vehicles for genetic medicines targeting kidney and pancreatic diseases. The company uses high-throughput in vivo screening to design tissue-specific viral vectors that are significantly more efficient and less immunogenic than existing alternatives.

Uncommon TherapeuticsUncommon Therapeutics uses advanced technologies to develop drugs targeting rare genetic diseases, starting with Rett Syndrome, a neurodevelopmental disorder affecting approximately 1 in 10,000 girls. The company combines disease expertise with efficient drug development to advance therapeutics from discovery to clinical application.

ParcelBioParcelBio develops APEXm, a proprietary mRNA platform that enhances protein expression for longer-lasting therapeutic effect compared to conventional mRNA technologies. The platform targets autoimmune disease, oncology, and therapeutic protein replacement applications.

BreezeBioBreezeBio develops a programmable platform called NanoGalaxy for targeted delivery of genetic medicines, aiming to move genetic payloads to specific cells and tissues. The company operates in the biotech and genetic therapeutics space.

Companies working in the same space as Algen Biotechnologies.

Legal entities · 1

corporate structure

Algen Biotechnologies, Inc.

Frequently asked questions

What does Algen Biotechnologies do?: Algen Biotechnologies discovers and develops small molecule therapeutics for cancer and inflammatory diseases using CRISPR, RNAi, and machine learning to decode functional gene networks and predict drug responses.
Who founded Algen Biotechnologies?: Algen Biotechnologies was founded by Chun-Hao Huang, Christine Du, Jennifer Doudna in 2018.
Who are Algen Biotechnologies's investors?: Algen Biotechnologies's investors include Cota Capital, Draper Associates, Lifespan Vision Ventures, Rebel Fund, Y Combinator, Sequoia Capital, Viking Global.
Where is Algen Biotechnologies headquartered?: Algen Biotechnologies is headquartered in San Francisco, US.